5 big analyst AI moves: Nvidia guidance warning; Snowflake, Palo Alto upgraded
Philip Astley-Sparke, a director at Replimune Group, Inc. (NASDAQ:REPL), has sold a portion of his holdings in the company. According to a recent SEC filing, Astley-Sparke sold 32,279 shares of Replimune common stock on May 20, 2025. The shares were sold at an average price of $8.06 each, resulting in a total transaction value of approximately $260,168. The stock, which currently trades at $8.76, has shown significant volatility with a 54.8% gain over the past year despite a 41.3% decline in the last six months. According to InvestingPro analysis, the company’s current market capitalization stands at $672 million.
The sale was conducted to cover tax withholding obligations related to the partial vesting of Restricted Stock Units (RSUs) and was executed under a pre-established "sell to cover" provision. This means the transaction was not a discretionary sale by Astley-Sparke. Following the sale, Astley-Sparke retains ownership of 1,405,071 shares of Replimune common stock. InvestingPro data shows the company maintains strong liquidity with a current ratio of 11.43 and holds more cash than debt on its balance sheet. For deeper insights into insider trading patterns and comprehensive financial analysis, including 10 additional ProTips, subscribers can access the full Pro Research Report.
In other recent news, Replimune Group Inc . reported its first-quarter earnings for 2025, showing a significant shortfall in expected earnings per share (EPS). The company recorded an EPS of -$3.07, considerably missing the forecasted -$0.72. Despite this earnings miss, Replimune’s cash and cash equivalents increased to $483.8 million, extending its cash runway into the fourth quarter of 2026. Additionally, Replimune’s key product, RP-one, received breakthrough therapy designation with a PDUFA date set for July 2025. The company is also expanding its operations with a new manufacturing facility and a 60-person commercial team. Replimune’s CEO, Sushil Patel, expressed confidence in RP-one’s market potential, especially for advanced melanoma patients. Analysts have noted the company’s substantial earnings miss, which may increase investor scrutiny and pressure on management. Nonetheless, Replimune remains focused on its strategic initiatives, including the commercialization of RP-one.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.